Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIBOCAL-CT is a combination pharmaceutical product developed and marketed by Uniark Healthcare, primarily formulated as a softgel capsule. It contains **calcitriol** (the active form of vitamin D3), **calcium carbonate**, and **zinc sulfate**. Calcitriol acts as a potent agonist at the vitamin D receptor (VDR), facilitating the intestinal absorption of calcium and phosphate and regulating bone mineralization. Calcium carbonate serves as a supplemental source of elemental calcium to maintain bone density and prevent bone loss. Zinc is included as an essential trace mineral that supports osteoblastic activity and collagen synthesis. The product is indicated for the management of conditions associated with calcium and vitamin D deficiency, such as osteoporosis, osteomalacia, and renal osteodystrophy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitriol + calcium carbonate + zinc sulfate.